<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
<PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
        <PMID Version="1">25897209</PMID>
        <DateCompleted>
            <Year>2016</Year>
            <Month>09</Month>
            <Day>13</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2018</Year>
            <Month>11</Month>
            <Day>13</Day>
        </DateRevised>
        <Article PubModel="Electronic-eCollection">
            <Journal>
                <ISSN IssnType="Electronic">1177-8881</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>9</Volume>
                    <PubDate>
                        <Year>2015</Year>
                    </PubDate>
                </JournalIssue>
                <Title>Drug design, development and therapy</Title>
                <ISOAbbreviation>Drug Des Devel Ther</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Targeting the hypoxia pathway to treat pancreatic cancer.</ArticleTitle>
            <Pagination>
                <MedlinePgn>2029-31</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.2147/DDDT.S80888</ELocationID>
            <Abstract>
                <AbstractText>The correlation between hypoxia and pancreatic cancer has long been discussed. Hao's research team made many efforts on revealing the oncogenic function of hypoxic inducible factor-1 (HIF-1) in pancreatic cancer progression and development in recent years. Based on their research, they linked micro-environmental regulation of pancreatic cancer and its clinical significance. Hao's research team suggests it is a promising approach to target HIF-1 for the management of pancreatic cancer progression and invasion. </AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Erickson</LastName>
                    <ForeName>Lori A</ForeName>
                    <Initials>LA</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Highsmith</LastName>
                    <ForeName>W Edward</ForeName>
                    <Initials>WE</Initials>
                    <Suffix>Jr</Suffix>
                    <AffiliationInfo>
                        <Affiliation>Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Fei</LastName>
                    <ForeName>Peiwen</ForeName>
                    <Initials>P</Initials>
                    <AffiliationInfo>
                        <Affiliation>University of Hawaii Cancer Center, University of Hawaii, Honolulu, HI, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Zhang</LastName>
                    <ForeName>Jun</ForeName>
                    <Initials>J</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <GrantList CompleteYN="Y">
                <Grant>
                    <GrantID>R01 CA188251</GrantID>
                    <Acronym>CA</Acronym>
                    <Agency>NCI NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
            </GrantList>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2015</Year>
                <Month>04</Month>
                <Day>08</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>New Zealand</Country>
            <MedlineTA>Drug Des Devel Ther</MedlineTA>
            <NlmUniqueID>101475745</NlmUniqueID>
            <ISSNLinking>1177-8881</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D000970">Antineoplastic Agents</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D051793">Hypoxia-Inducible Factor 1</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D000970" MajorTopicYN="N">Antineoplastic Agents</DescriptorName>
                <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000860" MajorTopicYN="N">Hypoxia</DescriptorName>
                <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
                <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D051793" MajorTopicYN="N">Hypoxia-Inducible Factor 1</DescriptorName>
                <QualifierName UI="Q000037" MajorTopicYN="Y">antagonists &amp; inhibitors</QualifierName>
                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D010190" MajorTopicYN="N">Pancreatic Neoplasms</DescriptorName>
                <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
                <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">HIF-1</Keyword>
            <Keyword MajorTopicYN="N">hypoxia</Keyword>
            <Keyword MajorTopicYN="N">pancreatic cancer</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2015</Year>
                <Month>4</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2015</Year>
                <Month>4</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2016</Year>
                <Month>9</Month>
                <Day>14</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>epublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">25897209</ArticleId>
            <ArticleId IdType="doi">10.2147/DDDT.S80888</ArticleId>
            <ArticleId IdType="pii">dddt-9-2029</ArticleId>
            <ArticleId IdType="pmc">PMC4396576</ArticleId>
        </ArticleIdList>
        <ReferenceList>
            <Reference>
                <Citation>PLoS One. 2012;7(8):e43399</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">22952674</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Cell Biochem. 2013 Nov;114(11):2603-11</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">23857671</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>PLoS One. 2014;9(3):e92824</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">24662981</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Anticancer Res. 2003 Nov-Dec;23(6C):4721-7</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">14981919</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cell. 2014 Sep 25;159(1):80-93</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">25259922</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cancer Res. 2015 Jan 1;75(1):111-9</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">25385028</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cancer Biol Ther. 2011 Sep 1;12(5):383-7</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">21709439</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cancer Res. 2014 May 1;74(9):2455-64</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">24599125</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
    </PubmedData>
</PubmedArticle>

</PubmedArticleSet>